

CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Company Registration No. 200505118M)

THE PROPOSED PLACEMENT OF 200,000,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY

Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meanings as defined in the announcement released on 8 March 2017, 10 March 2017 and 4 April 2017, in respect of, inter alia, the Proposed Share Placement (the “Previous Announcements”).

The board of directors (the “**Board**” of the “**Directors**”) of China Medical (International) Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refer to the Previous Announcements and wishes to announce that the Company has on 5 April 2017 completed the Proposed Share Placement, following the allotment and issuance of 200,000,000 Subscription Shares to the respective Subscribers at the Issue Price of S\$0.0072 per Subscription Share.

The Subscription Shares will be listed and quoted on the Official List of the Catalist of the SGX-ST.

The Subscription Shares shall rank *pari passu* in all respects with the existing issued shares of the Company, save that they do not rank for any dividends, distributions or entitlements the record date of which falls on or before the date of issue of the Subscription Shares.

Following the completion of the Proposed Share Placement, the total number of issued Shares of the Company has increased from 2,999,133,315 Shares to 3,199,133,315 Shares.

Further to the above, the Board wishes to provide an update on the use of the Share Placement Net Proceeds of approximately S\$1.42 million as at the date of this announcement, as follows:

Use of Proceeds	Amount allocated	Amount utilised as at the date of this announcement (S\$)	Balance as at the date of this announcement (S\$)
Funding Growth Expansion	426,000	127,609	298,391
General capital ⁽¹⁾ working	994,000	715,133	278,867
Net Proceeds	1,420,000	842,742	577,258

The above utilisations of proceeds are in line with the intended use as disclosed in the announcements dated 8 March 2017 and 10 March 2017.

Note:

- (1) The working capital portion of the placement proceeds was utilised for expenses relating to the operations of the Group which mainly related to the payment of general administrative and operating expenses.

By Order of the Board
5 April 2017

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Director, Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.